Coronary Restenosis
Drug-coated balloon remains superior to uncoated balloon for coronary in-stent restenosis
Confirming previously presented earlier results, a paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis.
FDA approves drug-coated balloon for the treatment of coronary in-stent restenosis
Boston Scientific announced the FDA approval of its drug-coated balloon indicated for the treatment of coronary in-stent restenosis in patients with coronary artery disease.
Revascularization after treatment of in-stent restenosis high after 10 years
SAN FRANCISCO — Among patients treated for drug-eluting in-stent restenosis, the revascularization rate at 10 years was high, according to the results of a post hoc analysis of the ISAR-DESIRE 3 trial presented at TCT 2023.
Drug-coated balloon bests uncoated balloon for coronary in-stent restenosis in AGENT IDE trial
SAN FRANCISCO — A paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis, according to the results of the AGENT IDE trial presented at TCT 2023.
Novel stent for long coronary lesions linked with low rate of target lesion failure
A novel 48-mm stent for the treatment of diffuse de novo coronary artery lesions was found to be safe and effective at 1 year, with a high level of device deliverability, a speaker reported.
Nearly 10% of PCIs performed for in-stent restenosis
PCIs performed on in-stent restenosis lesions are often treated with another stent, researchers found.
CAS-CARE: Cilostazol may inhibit in-stent restenosis after CAS
Cilostazol was associated with a trend toward reduction of in-stent restenosis in patients with carotid artery stenting at 2 years, according to findings presented at the International Stroke Conference.
BLADE-PCI: Novel liposomal alendronate fails in diabetes
SAN FRANCISCO — Intravenous administration of a novel liposomal formulation of alendronate at the time of PCI with drug-eluting stents failed to reduce restenosis at 9 months in patients with diabetes enrolled in the BLADE-PCI trial.
Sirolimus-eluting balloon given breakthrough device designation
Orchestra BioMed Inc., in partnership with Terumo Corporation, announced its sirolimus-eluting balloon for the treatment of below-the-knee peripheral artery disease, has received breakthrough device designation from the FDA.
Top intervention news of August: TAVR low-risk indications, FDA paclitaxel advisory and more
Healio compiled a list of the most-read cardiac and vascular intervention articles in August. This month, our readers were interested in the FDA approval of transcatheter aortic valve replacement devices for use in patients at low surgical risk, FDA recommendations on the signal of late mortality risk associated with paclitaxel-coated devices, the benefits of antiplatelet therapy in patients with atrial fibrillation who had TAVR and much more.